CIK 1802630
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 66.38% | 67 |
| Health Care Equipment & Supplies | 21.44% | 16 |
| Health Care Providers & Services | 8.98% | 5 |
| Unclassified | 3.14% | 4 |
| Professional Services | 0.05% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech, Inc. | Health Care | 12.06% |
| 2 | CELC | Celcuity Inc. | Health Care | 5.94% |
| 3 | TGTX | TG THERAPEUTICS, INC. | Health Care | 5.42% |
| 4 | PODD | INSULET CORP | Health Care | 4.78% |
| 5 | NVCR | NovoCure Ltd | Health Care | 4.63% |
| 6 | UTHR | UNITED THERAPEUTICS Corp | Health Care | 4.50% |
| 7 | PRAX | Praxis Precision Medicines, Inc. | Health Care | 4.31% |
| 8 | VCEL | Vericel Corp | Health Care | 3.32% |
| 9 | ALKS | Alkermes plc. | Health Care | 2.82% |
| 10 | ANIP | ANI PHARMACEUTICALS INC | Health Care | 2.55% |
89/93 names classified · sector 96.9% of weight · industry 96.9% · mkt cap 96.8%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 96.9% of the book is sector-classified (unclassified names shown, never dropped).
Only 38% of book weight classified — the grid is NOT representative of the whole book.
Classified: 37.6% of book weight (19/93 names) · unclassified 62.4%: KRYS, CELC, NVCR, PRAX, GERN, TWST, EWTX, BBNX, SNDX, NPCE +64 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | KRYSKRYSTAL BIOTECH INC | 1,153,087 | $298M | 12.1% | ADD 23% |
| 2 | CELCCELCUITY INC | 1,284,378 | $147M | 5.9% | TRIM −29% |
| 3 | TGTXTG THERAPEUTICS INC | 4,029,319 | $134M | 5.4% | ADD 28% |
| 4 | PODDINSULET CORP | 562,500 | $118M | 4.8% | ADD 275% |
| 5 | NVCRNOVOCURE LTD | 10,492,391 | $114M | 4.6% | ADD 23% |
| 6 | UTHRUnited Therapeutics Corp. | 187,187 | $111M | 4.5% | ADD 212% |
| 7 | PRAXPRAXIS PRECISION MEDICINES I | 330,517 | $106M | 4.3% | TRIM −9% |
| 8 | VCELVERICEL CORP | 2,549,079 | $82M | 3.3% | ADD 234% |
| 9 | ALKSALKERMES PLC | 1,970,864 | $70M | 2.8% | ADD 49% |
| 10 | ANIPANI PHARMACEUTICALS INC | 820,243 | $63M | 2.6% | ADD 69% |
| 11 | GMEDGLOBUS MED INC | 729,467 | $63M | 2.5% | TRIM −18% |
| 12 | GERNGERON CORP | 41,508,659 | $62M | 2.5% | ADD 78% |
| 13 | TWSTTWIST BIOSCIENCE CORP | 1,226,629 | $58M | 2.4% | TRIM −34% |
| 14 | EWTXEDGEWISE THERAPEUTICS INC | 1,449,915 | $46M | 1.8% | ADD 59% |
| 15 | BBNXBETA BIONICS INC | 4,354,501 | $44M | 1.8% | ADD 72% |
| 16 | ALNYALNYLAM PHARMACEUTICALS INC | 131,650 | $44M | 1.8% | ADD 88% |
| 17 | SNDXSYNDAX PHARMACEUTICALS INC | 1,726,908 | $40M | 1.6% | TRIM −23% |
| 18 | INDVINDIVIOR PHARMACEUTICALS INC COM | 1,274,000 | $39M | 1.6% | NEW |
| 19 | NPCENEUROPACE INC | 2,932,207 | $39M | 1.6% | ADD 8% |
| 20 | LIVNLIVANOVA PLC | 582,500 | $37M | 1.5% | ADD 3% |
| 21 | MIRMMIRUM PHARMACEUTICALS INC | 400,306 | $37M | 1.5% | TRIM −30% |
| 22 | BMRNBIOMARIN PHARMACEUTICAL INC | 650,572 | $37M | 1.5% | TRIM −51% |
| 23 | PGNYPROGYNY INC | 2,067,000 | $35M | 1.4% | NEW |
| 24 | INSPINSPIRE MED SYS INC | 576,299 | $30M | 1.2% | ADD 92% |
| 25 | FOCLEDAP TMS S A | 7,309,254 | $27M | 1.1% | HOLD |
| 26 | KNSAKINIKSA PHARMACEUTICALS INTL | 521,353 | $25M | 1.0% | TRIM −11% |
| 27 | MRKMERCK & CO INC | 203,000 | $24M | 1.0% | NEW |
| 28 | ORGOORGANOGENESIS HLDGS INC | 10,085,951 | $24M | 1.0% | HOLD |
| 29 | NTRANATERA INC | 119,000 | $24M | 1.0% | ADD 495% |
| 30 | AXGNAXOGEN INC | 679,170 | $23M | 0.9% | TRIM −44% |
| 31 | PCVXVAXCYTE INC | 385,472 | $22M | 0.9% | TRIM −37% |
| 32 | ICLRICON PLC | 192,000 | $21M | 0.9% | NEW |
| 33 | PHVSPHARVARIS N V | 702,052 | $20M | 0.8% | HOLD |
| 34 | CERSCERUS CORP | 10,753,700 | $20M | 0.8% | ADD 169% |
| 35 | TRVITREVI THERAPEUTICS INC | 1,620,000 | $19M | 0.8% | ADD 80% |
| 36 | IKTINHIBIKASE THERAPEUTICS INC | 10,875,000 | $18M | 0.7% | HOLD |
| 37 | CNTXCONTEXT THERAPEUTICS INC | 6,963,141 | $18M | 0.7% | NEW |
| 38 | VIRVIR BIOTECHNOLOGY INC | 2,002,000 | $18M | 0.7% | NEW |
| 39 | XENEXENON PHARMACEUTICALS INC | 292,000 | $17M | 0.7% | NEW |
| 40 | TVTXTRAVERE THERAPEUTICS INC | 546,000 | $16M | 0.7% | NEW |
| 41 | TNDMTANDEM DIABETES CARE INC | 783,000 | $15M | 0.6% | NEW |
| 42 | NRIXNURIX THERAPEUTICS INC | 938,163 | $15M | 0.6% | TRIM −23% |
| 43 | URGNUROGEN PHARMA LTD | 727,000 | $13M | 0.5% | ADD 385% |
| 44 | SIONSIONNA THERAPEUTICS INC | 293,500 | $12M | 0.5% | ADD 9% |
| 45 | CORTCORCEPT THERAPEUTICS INC | 285,531 | $12M | 0.5% | NEW |
| 46 | JBIOJADE BIOSCIENCES INC | 796,744 | $11M | 0.5% | HOLD |
| 47 | VCYTVERACYTE INC | 319,912 | $10M | 0.4% | ADD 3099% |
| 48 | IVVDINVIVYD INC | 7,708,727 | $10M | 0.4% | HOLD |
| 49 | CCCCC4 THERAPEUTICS INC | 3,803,942 | $10M | 0.4% | HOLD |
| 50 | KIDSORTHOPEDIATRICS CORP | 615,447 | $10M | 0.4% | ADD 17% |
| 51 | RCUSARCUS BIOSCIENCES INC | 451,983 | $10M | 0.4% | TRIM −37% |
| 52 | TNGXTANGO THERAPEUTICS INC | 450,000 | $9M | 0.4% | ADD 4400% |
| 53 | EOLSEVOLUS INC | 2,245,360 | $9M | 0.4% | ADD 110% |
| 54 | SOPHSOPHIA GENETICS SA | 1,850,000 | $9M | 0.4% | NEW |
| 55 | ELVNENLIVEN THERAPEUTICS INC | 230,869 | $9M | 0.4% | TRIM −77% |
| 56 | INBXINHIBRX BIOSCIENCES INC | 131,000 | $9M | 0.4% | ADD 424% |
| 57 | DXCMDEXCOM | 140,000 | $9M | 0.4% | TRIM −89% |
| 58 | SEPNSEPTERNA INC | 275,000 | $7M | 0.3% | TRIM −28% |
| 59 | AVTXAVALO THERAPEUTICS INC | 441,978 | $7M | 0.3% | HOLD |
| 60 | BDSXBIODESIX INC | 416,599 | $6M | 0.2% | NEW |
| 61 | RLMDRELMADA THERAPEUTICS INC | 842,106 | $6M | 0.2% | NEW |
| 62 | CGEMCULLINAN THERAPEUTICS INC | 410,200 | $6M | 0.2% | NEW |
| 63 | IMVTIMMUNOVANT INC | 230,000 | $6M | 0.2% | TRIM −79% |
| 64 | MBXMBX BIOSCIENCES INC | 178,897 | $5M | 0.2% | TRIM −56% |
| 65 | IMUXIMMUNIC INC | 4,500,000 | $5M | 0.2% | NEW |
| 66 | LRMRLARIMAR THERAPEUTICS INC | 1,066,960 | $5M | 0.2% | NEW |
| 67 | ETONETON PHARMACEUTICALS INC | 166,381 | $4M | 0.2% | NEW |
| 68 | SABSSAB BIOTHERAPEUTICS INC | 1,050,000 | $4M | 0.2% | NEW |
| 69 | PRCTPROCEPT BIOROBOTICS CORP | 160,000 | $4M | 0.2% | NEW |
| 70 | GPCRSTRUCTURE THERAPEUTICS INC | 80,000 | $4M | 0.2% | TRIM −11% |
| 71 | TECXTECTONIC THERAPEUTIC INC | 121,684 | $4M | 0.2% | NEW |
| 72 | LUNGPULMONX CORP | 2,788,323 | $4M | 0.1% | ADD 37% |
| 73 | IOVAIOVANCE BIOTHERAPEUTICS INC | 1,000,000 | $4M | 0.1% | NEW |
| 74 | ARGXARGENX SE | 3,500 | $3M | 0.1% | TRIM −89% |
| 75 | KPTIKARYOPHARM THERAPEUTICS INC | 440,000 | $2M | 0.1% | HOLD |
| 76 | MSLESATELLOS BIOSCIENCE INC | 414,359 | $2M | 0.1% | NEW |
| 77 | ARWRARROWHEAD PHARMACEUTICALS IN | 28,479 | $2M | 0.1% | NEW |
| 78 | NSPRINSPIREMD INC | 1,045,708 | $2M | 0.1% | TRIM −9% |
| 79 | INSMINSMED INC | 10,250 | $2M | 0.1% | TRIM −79% |
| 80 | CTMXCYTOMX THERAPEUTICS INC. | 300,000 | $1M | 0.1% | NEW |
| 81 | CGONCG ONCOLOGY INC | 20,000 | $1M | 0.1% | TRIM −88% |
| 82 | NEONEOGENOMICS INC | 175,000 | $1M | 0.1% | TRIM −59% |
| 83 | QNRXQUOIN PHARMACEUTICALS LTD | 72,730 | $480,018 | 0.0% | ADD 191% |
| 84 | COGTCOGENT BIOSCIENCES INC | 10,000 | $384,900 | 0.0% | TRIM −92% |
| 85 | TYRATYRA BIOSCIENCES INC | 10,000 | $383,000 | 0.0% | TRIM −92% |
| 86 | STAASTAAR SURGICAL CO | 20,000 | $374,000 | 0.0% | TRIM −20% |
| 87 | ANABANAPTYSBIO INC | 6,000 | $332,760 | 0.0% | TRIM −96% |
| 88 | RAPPRAPPORT THERAPEUTICS INC | 10,000 | $312,900 | 0.0% | NEW |
| 89 | RIGLRIGEL PHARMACEUTICALS INC | 10,000 | $270,400 | 0.0% | TRIM −97% |
| 90 | ZYMEZYMEWORKS INC | 10,000 | $250,400 | 0.0% | TRIM −90% |
| 91 | LBRXLB PHARMACEUTICALS INC | 10,000 | $246,600 | 0.0% | HOLD |
| 92 | ORKAORUKA THERAPEUTICS INC | 5,000 | $245,250 | 0.0% | TRIM −97% |
| 93 | JSPRJASPER THERAPEUTICS INC | 276,312 | $242,105 | 0.0% | ADD 38% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| KRYSKRYSTAL BIOTECH INC | 358K | 442K | 923K | 1.0M | 941K | 1.2M | $298M |
| CELCCELCUITY INC | 2.6M | 2.6M | 3.0M | 1.2M | 1.8M | 1.3M | $147M |
| TGTXTG THERAPEUTICS INC | 2.7M | 2.8M | 2.2M | 3.8M | 3.1M | 4.0M | $134M |
| PODDINSULET CORP | — | — | — | — | 150K | 563K | $118M |
| NVCRNOVOCURE LTD | 2.7M | 5.5M | 6.9M | 9.6M | 8.5M | 10.5M | $114M |
| UTHRUnited Therapeutics Corp. | 109K | 155K | 210K | 150K | 60K | 187K | $111M |
| PRAXPRAXIS PRECISION MEDICINES I | 244K | 1.1M | 967K | 859K | 363K | 331K | $106M |
| VCELVERICEL CORP | 81K | — | 51K | 498K | 764K | 2.5M | $82M |
| ALKSALKERMES PLC | — | — | — | — | 1.3M | 2.0M | $70M |
| ANIPANI PHARMACEUTICALS INC | 205K | 225K | 51K | 340K | 486K | 820K | $63M |
| GMEDGLOBUS MED INC | — | — | — | 176K | 887K | 729K | $63M |
| GERNGERON CORP | — | 2.4M | 16.1M | 17.3M | 23.3M | 41.5M | $62M |
| TWSTTWIST BIOSCIENCE CORP | — | — | 354K | 1.9M | 1.9M | 1.2M | $58M |
| EWTXEDGEWISE THERAPEUTICS INC | 183K | 72K | 76K | — | 910K | 1.4M | $46M |
| BBNXBETA BIONICS INC | — | 3.4M | 3.8M | 3.9M | 2.5M | 4.4M | $44M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
